Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 2/20 | 0.42 |
| ▸ | IL6ST | P40189 | 1/20 | 0.40 |
| ▸ | NAAA | Q02083 | 2/20 | 0.39 |
| ▸ | IDH1 | O75874 | 9/20 | 0.36 |
| ▸ | FAAH | O00519 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.35 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2273418 | 1.00 | PPARA (0.42) | PPARAIL6STNAAAIDH1FAAH | |
| SCHEMBL19899197 | 0.91 | PPARA (0.44) | PPARAIL6STNAAAIDH1FAAH | |
| SCHEMBL9007611 | 0.91 | PPARA (0.44) | PPARAIL6STNAAAIDH1FAAH | |
| SCHEMBL19899198 | 0.91 | PPARA (0.44) | PPARAIL6STNAAAIDH1FAAH | |
| SCHEMBL9007609 | 0.91 | PPARA (0.44) | PPARAIL6STNAAAIDH1FAAH | |
| SCHEMBL19899230 | 0.91 | PPARA (0.44) | PPARAIL6STNAAAIDH1FAAH | |
| SCHEMBL17497683 | 0.91 | PPARA (0.44) | PPARAIL6STNAAAIDH1FAAH | |
| SCHEMBL12418053 | 0.90 | PPARA (0.42) | PPARAIL6STNAAAIDH1FAAH | |
| SCHEMBL2193453 | 0.90 | PPARA (0.42) | PPARAIL6STNAAAIDH1FAAH | |
| SCHEMBL2193446 | 0.90 | PPARA (0.42) | PPARAIL6STNAAAIDH1FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030212067-A1 | Matrix metalloprotease inhibitors | CASTELHANO ARLINDO LUCAS (US) | 2003-11-13 | — | — | US | disclosed |
| US-6579890-B1 | Matrix metalloprotease inhibitors | SYNTEX (U.S.A.) INC. | 2003-06-17 | — | — | US | disclosed |
| US-6037472-A | FOR TREATING DISEASE-STATES CHARACTERIZED BY EXCESSIVE ACTIVITY OF MATRIX METALLOPROTEASES SUCH AS RHEUMATOID ARTHRITIS, OSTEOARTHRITIS, PERIODONTAL DISEASE, ABERRANT ANGIOGENESIS, TUMOR INVASION AND METASTASIS | SYNTEX (U.S.A.) INC. (US) | 2000-03-14 | — | — | US | disclosed |
| EP-0793643-A1 | MATRIX METALLOPROTEASE INHIBITORS | SYNTEX (U.S.A.) INC. (US) | 1997-09-10 | — | — | EP | disclosed |
| WO-1996016027-A1 | MATRIX METALLOPROTEASE INHIBITORS | SYNTEX (U.S.A.) INC. (US) | 1996-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212067-A1 | Matrix metalloprotease inhibitors | MMP7, MMP1, MMP3 | PPARA 4492/4885IL6ST 2231/4885NAAA 1401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.